Lead sponsor
Beijing Hospital
1 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.
1
Trials led
1
Active
115
Total enrollment
16
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Not applicable
1
Trials by status
Recruiting
1
Trials led
TrialKey I/E criterionPhaseStatusEnrollment
Comparing the Efficacy and Safety Between Continuous Subcutaneous Beinaglutide and CSII for Newly Diagnosed T2DM PatientsHbA1c 7.5-10%not applicableRecruiting115